BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance

  • BioMarin Pharmaceutical Inc BMRN reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues, partially offset by lower Kuvan product revenues. 
  • Vimizim and Naglazyme sales increased 47% to $171.7 million and $118.8 million, respectively, primarily driven by the timing of orders from Europe and the Middle East.
  •  Palynziq sales increased 45% to $59 million, primarily driven by a combination of revenue from more U.S. patients achieving maintenance dosing and new patients initiating therapy.
  • Kuvan product revenues declined 36% to $78.8 million due to generic competition due to the loss of exclusivity in the U.S.
  • The Company turned to profit as EPS came in at $0.07, ahead of the consensus of $(0.11). Adjusted income increased to $97.8 million from $57.4 million a year ago.
  • Guidance: BioMarin raised its FY21 guidance with sales of $1.79 billion - $1.88 billion (consensus $1.82 billion), compared to the earlier outlook of $1.75 billion - $1.85 billion.
  • It forecasts adjusted income of $190 million - $240 million, compared to previous guidance of $170 million - $220 million.
  • Price Action: BMRN shares closed at $78.73 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!